We evaluated the results of high-dose therapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with relapsed or primary refractory Hodgkin’s disease (HD), using a previously reported prognostic model based on the presence of three poor prognostic factors at the start of salvage therapy/preparative regimen: B symptoms, extranodal disease and the duration of last complete response of less than 1 year. Based on this model, the patients were divided into low-risk and high-risk groups. Between 1993 and 2001, 24 patients with HD were treated with HDT and ASCT. Eighteen of the 24 patients had 0–1 risk factors (low-risk group) and 6 patients had 2–3 risk factors (high-risk group). Using Kaplan-Meier analysis, after a median follow-up of 40.5 months, the progression-free survival (PFS) was 48%, and the overall survival (OS) was 55%. PFS in the low-risk group was 56%, and in the high-risk group 17% (p < 0.001). OS in the low-risk group was 68% and in the high-risk group it was 18% (p < 0.001). The 100-day transplant-related mortality for the entire group was 16%. Our results are comparable to those reported in previous clinical trials for patients with refractory and relapsed HD treated with HDT and ASCT. The use of a prognostic model appears useful for predicting the outcome of HDT and ASCT for HD patients, and may play an important role in choosing the appropriate therapy for these patients.

Keywords:
Autologous stem cell transplantation, High-dose therapy, Hodgkin’s disease, Prognostic model, Progression-free survival
1.
Urba WJ, Longo DL: Hodgkin’s disease (review). N Engl J Med 1992;326:678–687.
2.
DeVita VT Jr, Hubbard SM: Hodgkin’s disease (review). N Engl J Med 1993;328:560–565.
3.
Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 1987;5:556.
4.
Tourani JM, Levy R, Colonna P, Desablens B, Leprise PY, Guilhot F, Brahimi S, Belhani M, Ifrah N, Sensebe L: High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin’s disease. J Clin Oncol 1992;10:1086–1094.
5.
Arranz R, Tomas JF, Gil-Fernandez JJ, Martinez-Chamorro C, Granados E, Alegre A, Figuera A, Vazquez L, Camara R, Fernandez-Ranada JM: Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin’s disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998;21:779–786.
6.
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent and refractory Hodgkin’s disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–813.
7.
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
8.
Nademanee A, O’Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: Results in 85 patients with analysis of prognostic factors. Blood 1995;85:1381–1390.
9.
Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1991;9:1871–1879.
10.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet 2002;359:2065–2071.
11.
Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO: High dose chemotherapy followed by ASCT in HD: Long-term follow-up in 128 patients. Ann Oncol 1993;4:767–773.
12.
Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D: High-dose etoposide and melphalan and ABMT for patients with advanced HD: Importance of disease status at transplant. J Clin Oncol 1993;11:704–711.
13.
Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH: High dose therapy and ASCT for patients with HD in first relapse after chemotherapy: Results from the EBMT. Bone Marrow Transplant 1997;20:745–752.
14.
Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O’Brien JP, Straus D, Portlock CS, Yahalom J: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’s disease: Analysis of intent to treat and development of a prognostic model. Blood 2001;97:616–623.
15.
Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O’Reilly S, Shepherd JD, Sutherland HJ: Intensive therapy with cyclophosphamide, carmustine, etoposide +/– cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 1994;83:1193–1199.
16.
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E 3rd, Kadin M, Antin J: High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: A prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98–106.
17.
Herzig GP: Autologous marrow transplantation in cancer therapy. Prog Hematol 1981;12:1.
18.
Klingemann HG, Wilkie-Boyd K, Rubin A, Onetto N, Nantel SH, Barnett MJ, Reece DE, Shepherd JD, Phillips GL: Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin’s disease. Biotechnol Ther 1994;5:1–13.
19.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.